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Impact and challenges of Alzheimer’s disease
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Alzheimer’s disease (AD) is neurodegenerative and represents one of the most common forms of 
dementia in the elderly population. Dementia causes a progressive decline in cognitive domains, behavioral 
changes, loss of skills and difficulties in performing activities of daily living (ADLs), which causes suffering 
to patients and their families1,2. A retrospective study published recently showed that dementia was diagnosed 
in 68.8% of patients, with AD being confirmed in 48.9% of the cases2. A recent systematic review and meta-
analysis study showed that the number of people living with dementia doubles approximately every five 
years1. This same survey also revealed that, in the general analysis, the prevalence was higher in women 
than in men (788 cases versus 561 cases per 10,000 individuals). When analyzed individuals aged 60-69 
years, prevalence of AD in female was 1.9 times higher than in male (108 cases versus 56 cases per 10,000 
individuals)1.
We must consider that, currently, the population aging process is a global reality, and consequently, 
these conditions have become even more prevalent, placing us in front of a significant public health problem2. 
Today in Brazil, according to the Brazilian Alzheimer’s Association (ABRAz), there are about 1.2 million 
cases, most of them still undiagnosed. By 2050, it is estimated that around 115 million individuals will have 
this type of dementia. 
AD is mainly characterized by deposition of β-amyloid plaques in the intraneural spaces, as well 
as hyperphosphorylation of the tau protein, with the formation of neurofibrillary tangles in intracellular 
level1,3. Diagnosis of AD has a predominantly clinical character and is carried out through the patient’s 
anamnesis and assessment of family history and disease. The definitive confirmation that the individual was 
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affected by AD requires an assessment of his post-mortem brain tissue; however, the clinical specifications 
in conjunction with the use of cerebrospinal fluid biomarkers and emission tomography may help in the 
diagnosis of patients still in their lifetimes3.
As for the etiology, most cases have complex inheritance, that is, it is the result of an interaction 
of genetic and environmental factors, which cause cerebral atrophy and decline in the affected patient’s 
cognitive functions. Risk factors for Alzheimer’s disease include age, genetics, depression and hypertension. 
Cerebrovascular diseases, diabetes, obesity and dyslipidemia also increase the risk of developing AD. On 
the other hand, listening to music daily, meeting weekly with friends, daily intake of vitamin E, performing 
physical activity as well as a balanced diet were considered protective factors4,5.
There is a consensus in the literature about the role of the APP genes (in English: “Amyloid Beta 
Precursor Protein”), PSEN1 (Presenilin 1), PSEN2 (Presenilin 2) and APOE (Apolipoprotein E) in the 
development of AD6, focusing on mutations and genetic polymorphisms. In the past 10 years, more than 40 
genes/loci have been linked to the risk of Alzheimer’s disease. However, our knowledge of genetics, with 
regard to AD, is far from complete, and further genetic studies and post-GWAS analyzes are essential7.
Another interesting approach in AD refers to lipidomics, since the brain is highly enriched in lipids 
and the interruption of lipid homeostasis is related to neurological disorders, as well as neurodegenerative 
diseases, such as AD8. Thus, considering that aging is associated with changes in lipid composition, it is 
suggested that the study of lipidome may contribute to the identification of biomarkers for prevention, 
diagnosis and prognosis, as well as for the discovery of new therapeutic options7. According to a research 
conducted by the authors, genetic polymorphisms associated with AD were identified, as shown in Chart 19. 
Our data reinforce the role of lipid metabolism genes in AD pathogenesis.
Since AD  is characterized as a highly disabling disease, resulting in a significant reduction in the 
quality of life of the affected elderly and their caregivers, with a consequent loss of autonomy and independence 
in ADLs, understanding the pathophysiology of AD may allow better prognosis. Thus, the identification of 
genetic and/or lipid biomarkers is important, as it favors the implementation of early treatment strategies with 
the minimization of cognitive and psychomotor limitations. In addition, early treatment is able to provide a 
better quality of life not only to the patient affected, but also to those around him.
Chart 1 - Identification of genetic polymorphisms associated with Alzheimer’s disease, according to the genes acronyms 
and action mechanisms involved.
Genes Action that the gene participates
ApoE, CD36, ABCA7, ABCA1, APOC1, MPO, PON1 and PSEN2. Lipid metabolism
OGG1 Repair systems
NGF Nerve regeneration
CHI3L1, CHRM2, CHRM3 Cellular responses
BIN 1, SORL1, BCAM, NECTIN 2, DLST AND PICALM Coding of proteins of different functions.
TOMM40 Mitochondrial metabolism
Source: The authors (2020)
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